IPA 240816 2.50C (IPA240816C2500) Stock Options, News & Quotes

0.04
0.000.00%

15min DelayClose Aug 6 16:00 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Jul 17 00:33

NEWS

$ImmunoPrecise Antibodies(IPA.US)$
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
ImmunoPrecise Antibodies (IPA) has entered into a $3.0 million convertible debenture agreement with Yorkville Advisors Global, LP. The deal includes two tranches: $2.0 million completed on July 16, 2024, and $1.0 million pending SEC approval. Key features:
- 8.0% annual interest rate
- Convertible to comm...

Jaguar8

Jun 25 06:28

NEWS

$ImmunoPrecise Antibodies(IPA.US)$
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
ImmunoPrecise Antibodies (IPA) announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI to develop an AI model for pharmacogenomics, leveraging BioStrand's LENSai technology. This partnership aims to enhance precision medicine by integrating AI with vast genomic data to improve pa...

Stock Region

Jun 11 10:22

Biotherapeutic Technology Company Announces Commercial Offering For AI-Driven Drug Discovery

ImmunoPrecise Antibodies Subsidiary BioStrand Announces Immediate Commercial Offering Of Software With Customizable Interface For AI-Driven Drug Discovery.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a company in AI-driven biotherapeutic research and technology, has announced the immediate commercial release of its subsidiary BioStrand’s new software offering, LENSai API. This advanced software solution,...

Trytosaveabit

Jun 10 06:18

Update

$ImmunoPrecise Antibodies(IPA.US)$ Reuters· 1 min ago
Biostrand, Immunoprecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software With Customizable Interface for AI-Driven Drug Discovery

Jaguar8

Apr 22 08:15

$ImmunoPrecise Antibodies(IPA.US)$
NEWS
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 /ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TMPlatform. LENSai, which is run by the company's subsidiary, BioStrand, provides a ...